Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8
01 Mai 2007 - 7:21PM
PR Newswire (US)
WESTMINSTER, Colo., May 1 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), today announced that it will
report its 2007 first quarter financial results on Tuesday, May 8,
2007, before the open of the U.S. financial markets. Paul L. Berns,
President and Chief Executive Officer, and other members of Allos'
senior management will provide a company update and summary of
first quarter results via webcast and conference call on Tuesday,
May 8, 2007 at 8:30 AM ET. The dial in number for U.S. residents to
participate is 877-407-8031. International callers should dial
201-689-8031. Participants should reference the Allos Therapeutics
conference call. An audio replay of the conference call will be
available from 5 PM ET on Tuesday, May 8, 2007, until 11:59 PM ET
on Friday, May 18, 2007. To access the replay, please dial
877-660-6853 (domestic) or 201-612-7415 (international); Replay
pass codes (both required for playback): account # 286; conference
ID # 239702. The webcast of this call will be available from the
homepage and the investors/media section of the Company's web site,
http://www.allos.com/ and will be archived for 30 days. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company has two product candidates in late-stage
clinical development: EFAPROXYN(TM) (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in
women with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel antifolate currently under evaluation in a
pivotal Phase 2 trial in patients with relapsed or refractory
peripheral T-cell lymphoma. The Company is also evaluating RH1, a
targeted chemotherapeutic agent, in a Phase 1 trial in patients
with advanced solid tumors. For additional information, please
visit the Company's website at http://www.allos.com/. Safe Harbor
Statement The 2007 first quarter results press release and
conference call will contain forward-looking statements that
involve significant risks and uncertainties, including those that
can be found in the "Risk Factors" section of Allos' Form 10-K for
the year ended December 31, 2006 and in Allos' periodic reports on
Form 10-Q and Form 8-K. Allos is providing the information
contained in the press release and conference call as of the date
of the release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
press release or the conference call. No forward-looking statement
can be guaranteed and actual events and results may differ
materially from those projected. DATASOURCE: Allos Therapeutics,
Inc. CONTACT: Jennifer Neiman, Senior Manager, Corporate
Communications, +1-720-540-5227, , or Derek Cole, Vice President,
Investor Relations, +1-720-540-5367, , both of Allos Therapeutics,
Inc. Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics (MM)